AbCellera Biologics (ABCL) Enterprise Value (2020 - 2025)
AbCellera Biologics (ABCL) has disclosed Enterprise Value for 6 consecutive years, with -$520.7 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 22.07% year-over-year to -$520.7 million, compared with a TTM value of -$520.7 million through Sep 2025, up 22.07%, and an annual FY2024 reading of -$181.3 million, down 488.72% over the prior year.
- Enterprise Value was -$520.7 million for Q3 2025 at AbCellera Biologics, down from -$117.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$30.8 million in Q4 2023 and bottomed at -$1.0 billion in Q2 2022.
- Average Enterprise Value over 5 years is -$506.7 million, with a median of -$520.7 million recorded in 2025.
- The sharpest move saw Enterprise Value surged 92.52% in 2023, then plummeted 488.72% in 2024.
- Year by year, Enterprise Value stood at -$501.1 million in 2021, then grew by 17.88% to -$411.5 million in 2022, then soared by 92.52% to -$30.8 million in 2023, then tumbled by 488.72% to -$181.3 million in 2024, then plummeted by 187.15% to -$520.7 million in 2025.
- Business Quant data shows Enterprise Value for ABCL at -$520.7 million in Q3 2025, -$117.4 million in Q2 2025, and -$630.3 million in Q1 2025.